Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved ECALTA er større end risiciene, når det anvendes til behandling af voksne, ikke- neutropene patienter med invasiv candidiasis.
The Committee for Medicinal Products for Human Use (CHMP) concluded that ECALTA’ s benefits are greater than its risks in the treatment of invasive candidiasis in adult non-neutropenic patients.